Effect of Zofenopril on regeneration of sciatic nerve crush injury in a rat model

<p>Abstract</p> <p>Background</p> <p>Zofenopril is an antioxidant agent which has been shown to have beneficial effects in hypertension and heart failure. The aim of this study was to test the effects of Zofenopril on nerve regeneration and scarring in a rat model of peripheral nerve crush injury.</p> <p>Methods</p> <p>Twenty-one adult Sprague-Dawley rats underwent a surgical procedure involving right sciatic nerve crush injury. 15 mg/kg Zofenopril was administered orally to seven rats in group Z for seven days. Seven rats in group S received saline orally for seven days. Seven rats in the control group C received no drug after crush injury. Fourteenth and 42nd days after injury, functional and electromyography assessments of nerves were performed. Functional recovery was analyzed using a walking track assessment, and quantified using the sciatic functional index (SFI). After these evaluations, all rats were sacrificed and microscopic evaluations were performed.</p> <p>Results</p> <p>The Sciatic functional Index (SFI) in group Z on 14^thday is different significantly from group S and group C (p = 0.037). But on 42^ndday there was no difference between groups (p = 0.278). The statistical analyses of electromyelographic (EMG) studies showed that the latency in group Z is significantly different from group S (p = 0.006) and group C (p = 0.045). But on 42^ndday there was no difference between groups like SFI (p = 0.147). The amplitude was evaluated better in group Z than others (p < 0.05). In microscopic evaluation, we observed the highest number of nerve regeneration in the group Z and the lowest in the group C. But it was not significant statistically.</p> <p>Conclusion</p> <p>Our results demonstrate that Zofenopril promotes the regeneration of peripheral nerve injuries in rat models.</p

The effect of erythropoietin on biomechanical properties of the Achilles tendon during the healing process: an experimental study

Tensile test data. (XLSX 10 kb

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

Measurement of Bone Mineral Density in Male Detainees

Aim: We aimed to investigate the increased risk for osteoporosis due to closed environment and sedentary lifestyle of prisoners. In this way, we planned to inform prisoners and supervisors for protective measures that should be taken if low bone mineral density (BMD) is detected compared with normal population. Materials and Methods: Sixty six prisoner men over the age of 45 as the study group and 66 male volunteers who are not detainees over the age of 45 as a control group were included in the study. All participants' age, occupation, duration in prison, habits, nutrition, exercise, diseases and medications used were noted. BMD values were measured using a phalangeal radiographic absorptiometry (Alara Metriscan®). Results: BMD values in the study group were measured as 0.341±0.030 g/cm2 and as 0.346±0.029 g/cm2 in the control group (p=0.968). BMD values of the study group were lower than those of the control group. Conclusion: In this study, we found that BMD values of the detainees were lower than those of the control group but this difference was not statistically significant. However, there was a negative correlation between BMD values and duration in prison. (Turkish Journal of Osteoporosis 2012;18: 81-5

Percutaneous surgery using Admix NoKorTM Non-Coring 16 G needle in cases with trigger finger

In this study mid- and long-term outcomes of the cases with trigger finger we treated using Admix NoKorTM have been presented. Percutaneous release procedures were applied for 24 fingers of 22 (19 female, 3 male patients; mean age, 57; range, 39-72) patients between May 2009 and May 2011. Preoperatively US was performed so as to confirm the presence of trigger finger. Diameters of the tendons of the affected and intact hands measured using US, were compared so as to be able to demonstrate thickening of the tendon of the trigger finger. The patients were monitored for an average period of 25.2 (range, 14-36) months. During surgery, clinically loss of the catching sensation was observed. In two patients percutaneous trigger finger release failed, so we have to proceed with open surgery. During open surgery, we observed longitudinal wounds on the tendon. One patient developed unilateral radial digital nerve damage. Percutaneous release of the trigger finger using Admix NoKorTM 16-G gauge needle can be preferred in the treatment of trigger finger. Trigger finger of the first digit requires more attentive approach and one should be aware of the complications. If required open surgery can be preferred. [Med-Science 2017; 6(3.000): 551-6

Mitchell's Osteotomy With Mini-Plate and Screw Fixation for Hallux Valgus

WOS: 000330306300012PubMed: 23413064Background: The aim of this study was to evaluate the use of mini-plate and screw fixation to stabilize the first metatarsal osteotomy in patients undergoing Mitchell bunionectomy, with the outcomes of interest being radiological alignment and the time to bony union. Methods: We used mini-plates and screws in 43 feet of 25 patients to avoid cast immobilization and prevent osteotomy displacement. The mean age at operation was 45.4 +/- 13.4 years (range, 17.0-65.0 years). The mean follow-up was 16.9 +/- 3.6 months (range, 12.0-30.0 months). The hallux valgus angles, intermetatarsal angles, and American Orthopaedic Foot and Ankle Society (AOFAS) forefoot scores were evaluated preoperatively and at postoperative month 12. Results: The mean preoperative value for the hallux valgus angle was 35.9 +/- 4.4 degrees (range, 26.0-45.0 degrees) and for the intermetatarsal angle was 12.1 +/- 1.4 degrees (range, 10.0-15.0 degrees). The mean postoperative value for the hallux valgus angle was 16.0 +/- 2.12 degrees (range, 12.0-20.0 degrees) and for the intermetatarsal angle was 7.7 +/- 1.2 degrees (range, 5.0-10.0 degrees). The mean AOFAS score was 50.5 +/- 12.8 points (range, 30.1-76.0 points) preoperatively and 75.9 +/- 11.3 points (range, 43.3-92.3 points) at postoperative month 12. Improvement of range of motion of the metatarsophalangeal joint, pain relief, and satisfactory alignment of the first ray were achieved in 41 feet (95.3%). Conclusions: We recommend this fixation for Mitchell's bunionectomy because it provided stable fixation without the need for casting

Multiple Intraosseous Lipoma: Report of Three Cases

WOS: 000298576600009Multiple intraosseous lipoma (MIOL) is extremely rare bone tumour, Its real incidence is estimated as much more because of most of these tumours is asymptomatic and undiagnosed. We reported 3 MIOL patients involving both upper and lower extremity. Two female patient with 30 and 26 age and one male with 52 years old represented by intraosseous lipomatous lesions involving bilateral wrist and hand bones, distal radius, proximal and distal femur, patella, proximal and distal tibia metaphyses, distal fibula, ankle and foot bones. Painful lesions were curetted and grafted by allograft. A distal radius fracture is treated by closed reduction and percutaneus pining. All the lesions healed that is managed by surgery. The asymptomatic lesions were not treated anyway. MIOL needs surgery in the case of pain, pathologic fracture, pathologic diagnosis confirmation and impending fracture. The malign transformation potential is present even rare. It must be followed in long period and carefully. CT is a good diagnostic imaging allowing negative density measurement in lesions between -60 and -110 HU

The effect of tramadole HCL and paracetamol on fracture healing in rat tibia model

In our research, we aim to study the effects of combined usage of tramadole HCl + paracetamol on rat tibia fracture model. In our study, 60 Wistar-Albino type male rats, weighted at 300-350 g., were divided as control and test ( tramadole HCl + paracetamol) groups Under general anesthesia, standard closed fractures were created on right tibias of all rats using blunt ended needle holder with three point principle and then closed reduction and fixing with intramedullary nail (0.7 mm) were provided. After fracture treatment of 30 rats in the test group, starting at the same day, 40mg/kg/day tramadole HCL was introduced as daily intermuscular dosage until they were sacrificed. Rats were sacrificed after the fractures as groups of 10 individuals at 2nd, 4th and 6th weeks. Healing fractured tibias were examined mechanically, radiologically, histopathologically. Results: No positive or negative radiological, biochemical and histological effect was detected after the long duration of tramadole HCL + paracetamol usage, starting from the first day and reaching to 6 weeks, in healing process of closed tibia fractures created and fixed with IM nails in rats. Considering the negative effects of NSAIDs on fracture healing, we think that tramadole HCl + paracetamol combination is a safe option in postoperative pain treatment after fracture. [Med-Science 2017; 6(1.000): 81-5